Ozempic® vs. Wegovy®: what’s the difference?

By

Editorial Team

|

August 27, 2024

A man preparing an Ozempic® injection, illustrating the use of semaglutide for managing blood sugar levels, in the comparison between Ozempic® and Wegovy®

Medical Review by Jennie Stanford, MD, FAAFP, DipABOM

Summary

  • Ozempic® is FDA-approved for treating type 2 diabetes, while Wegovy® is FDA-approved for weight management in adults who are  overweight with >1 weight-related comorbidity or obese.
  • Wegovy® contains a higher dosage of semaglutide compared to Ozempic®.  Both drugs have the same active ingredient and work in the same way but were developed and approved for different purposes (weight loss vs. blood sugar control).
  • Because both medications are semaglutide, just in different dosages, they have similar side effect profiles. Common side effects include nausea, vomiting, and diarrhea.
  • Rare or severe side effects can include hypoglycemia, acute pancreatitis,, an increased heart rate, gallstones, possible kidney damage, thyroid cancer risk, and an increased risk of diabetic retinopathy. Wegovy® may also cause headache, fatigue, and hair loss.
  • Always talk to a qualified healthcare provider before obtaining or using either medication, and use them only as prescribed.

Ozempic® & Wegovy® both use semaglutide—but they aren’t exactly alike

Ozempic® and Wegovy® are two GLP-1 agonist medications that are currently getting a lot of media attention—but while they both use semaglutide, there are important differences between them.

We’ve put together this comparison to help you understand more about both medications. Use this information to have better conversations with your healthcare provider and make informed decisions for your long-term wellness.

How semaglutide & other GLP-1 agonists work

Semaglutide (the active ingredient in both Ozempic® and Wegovy®) is a type of medication called a GLP-1 agonist. GLP-1 agonists work by mimicking a natural hormone called GLP-1, which helps control blood sugar levels.

Your body normally releases GLP-1 when you eat, which tells your pancreas to produce insulin. Insulin helps lower blood sugar by allowing cells to take in glucose.

In people with type 2 diabetes, this process often doesn’t work well, so GLP-1 agonists help by boosting insulin production when needed. But they have other effects as well—like making you feel less hungry.

Why people use Ozempic® & Wegovy®

Although Ozempic® and Wegovy® both use semaglutide, they are FDA-approved for different uses. Here are the intended uses of each medication:

  • Ozempic® is FDA-approved for treating type 2 diabetes by lowering your blood sugar levels if other approaches like diet and exercise aren’t enough on their own. Learn more by reading our Ozempic® guide here.
  • Wegovy® is FDA-approved for weight management in adults who are overweight with >1 weight-related comorbidity or  obese. It helps with weight loss by slowing gastric emptying and sending signals to the parts of your brain that tell you when you are full. Learn more by reading our Wegovy® guide here.

Both Ozempic® and Wegovy® work by being injected under the skin.  They are only available with a prescription. That means you’ll need to talk with a qualified healthcare practitioner before you can obtain and use them.

What makes Ozempic® & Wegovy® different

So if both medications contain semaglutide (a GLP-1 receptor agonist), then why are they used for different things? Why aren’t they interchangeable?

The answer is that Wegovy® contains more semaglutide than Ozempic® does. This is due to the fact that both medications were initially developed for different purposes.

The development process for Ozempic® focused on finding the amount of semaglutide that was most effective for lowering blood sugar in people with type 2 diabetes, while the development process for Wegovy® focused on finding the amount of semaglutide that was best for weight loss. For this reason, the trials for Wegovy® focused on adults without diabetes, while the trials for Ozempic® focused on patients with type 2 diabetes.

Warning: Risk of Thyroid C-Cell Tumors

Wegovy® and Ozempic® have been linked to a risk of thyroid C-cell tumors based on animal studies. Specifically, in rodent studies, semaglutide, the active ingredient in Wegovy® and Ozempic®, have been shown to cause thyroid C-cell tumors at clinically relevant exposures. Although the risk to humans has not been conclusively established, it is essential to be aware of the following precautionary measures.

Side effects for semaglutide

Since Ozempic® and Wegovy® use different amounts of semaglutide, understanding its side effects and only taking either of these medications in the amount prescribed to you by a healthcare provider is an essential part of using them appropriately. Here’s a breakdown of the side effects semaglutide can have:

Common Side Effects

  • Nausea
  • Vomiting
  • Diarrhea

Rare or Severe Side Effects

Mild allergic reactions are also possible at the injection site—so it’s important to inject either medication carefully and check the site often to make sure it isn’t irritated.

Additional side effects for Wegovy®

Wegovy®, which has a higher concentration of semaglutide than Ozempic® may have several additional side effects. These include more common side effects like headache and fatigue, as well as hair loss.

It’s important to note that these are not all the possible side effects of either medication, and that research into both medications is still ongoing. Always talk to your primary care provider and make sure you understand the risks before trying either Ozempic® or Wegovy®.

Ozempic® vs. Wegovy® at a glance

Based on the information above, here’s a quick comparison chart to help you understand what each of these medications are for—as well as what makes them different:

 Ozempic®Wegovy®
Active IngredientSemaglutideSemaglutide
Maximum Dose2mg2.4 mg
Method of AdministrationInjectionInjection
FDA-Approved UseLowering blood sugar for patients with type 2 diabetes (when other methods have failed)Weight loss or management in overweight or obese adults and children age 12 or older
Common Side EffectsNauseaVomitingDiarrheaNauseaVomitingDiarrheaHeadacheFatigue
Rare Side EffectsLow blood sugarAcute pancreatitisThyroid cancerGallstonesIncreased heart ratePossible kidney damageIncreased risk of diabetic retinopathyLow blood sugarAcute pancreatitisThyroid cancerGallstonesIncreased heart ratePossible kidney damageIncreased risk of diabetic retinopathyHair loss (most likely due to stress)

Learn more about Ozempic® & Wegovy® with Lemonaid Health

Semaglutide and other GLP-1 agonists have several valid uses, and it’s natural to be curious about what medications like Ozempic® and Wegovy® might be able to do for you if you have either type 2 diabetes or are struggling to manage your weight. But it’s also important to understand the risks that come with these medications—and to remember that Ozempic® and Wegovy® are different formulations of semaglutide with different uses.

Talking to a healthcare professional can help you learn more about whether either of these medications are right for you. 

Lemonaid Health can help you access online consultations with US-based medical professionals to answer your questions about either of these medications and take appropriate next steps. Get started with a visit here.

Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S.

  1. Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2021). Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine, 70(1), jim-2021-001952. Accessed July 15, 2024 at https://doi.org/10.1136/jim-2021-001952
  2. Collins, L., & Costello, R. A. (2023). Glucagon-like peptide-1 receptor agonists. PubMed; StatPearls Publishing. Accessed July 15, 2024 at https://www.ncbi.nlm.nih.gov/books/NBK551568/
  3. FDA. (2020). Drug Trial Snapshot: Ozempic. FDA. Accessed July 15, 2024 at https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-ozempic
  4. FDA. (2021, June 4). FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. FDA. Accessed July 15, 2024 at https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
  5. Magda Sara Wojtara, Mazumder, A., Syeda, Y., & Nikodem Mozgała. (2023). Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management. Advances in Medicine, 2023, 1–7. Accessed July 15, 2024 at https://doi.org/10.1155/2023/9946924
  6. HIGHLIGHTS OF PRESCRIBING INFORMATION. (2017). Accessed July 15, 2024 at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
  7. Smits, M. M., & Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in Endocrinology, 12. Accessed July 15, 2024 at https://doi.org/10.3389/fendo.2021.645563
  8. Mathew, P., & Thoppil, D. (2022). Hypoglycemia. National Library of Medicine; StatPearls Publishing. Accessed July 15, 2024 at https://www.ncbi.nlm.nih.gov/books/NBK534841/
  9. Gapp, J., Chandra, S., & Tariq, A. (2023, February 9). Acute pancreatitis. PubMed; StatPearls Publishing. Accessed July 15, 2024 https://www.ncbi.nlm.nih.gov/books/NBK482468/
  10. Tanaja, J., & Meer, J. M. (2019). Cholelithiasis. Nih.gov; StatPearls Publishing. Accessed July 15, 2024 at https://www.ncbi.nlm.nih.gov/books/NBK470440/
  11. Perkovic, V. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine/The New England Journal of Medicine. Accessed July 15, 2024 at https://doi.org/10.1056/nejmoa2403347
  12. National Eye Institute. (2019). Diabetic Retinopathy | National Eye Institute. Nih.gov. Accessed July 15, 2024 at https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/diabetic-retinopathy
  13. WegovyTM (semaglutide injection) Product Monograph READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE. (n.d.). Accessed July 15, 2024 at https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/Wegovy-consumer-information.pdf
  14. Kommu S, Whitfield P. Semaglutide. [Updated 2024 Feb 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK603723/ 
  15. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., Ryan, D. H., & SELECT Trial Investigators (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563 

By

Editorial Team

|

August 27, 2024

This article is for informational purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. Always talk to your doctor about the risks and benefits of any treatment or medication.